MBI Distributing, Inc. has been ordered to stop manufacturing its over-the-counter (OTC) eye drops and pain relief drugs. The FDA found that manufacturing deficiencies resulted in the company being unable to ensure that its eye drops were sterile. Also, the FDA determined that two of MBIs eye drop brands, Visitein and Clarity Vision for Life, are unapproved drugs. Further, the FDA found that Biogesic, Bio-Ice, and Bio-Heat, three of MBIs OTC pain relief drugs, have inadequate warnings for their safe use. The FDA has recommended that consumers and health care providers dispose of Oxydrops, Bright Eyes, Bright Eyes II, Clarity Vision for Life, Visitein, and Can-C eye drops and the Biogesic, Bio-Ice and Bio-Heat pain relieving drugs.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.